Discontinued — last reported Q4 '25
Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
Revolution Medicines, Inc. Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan remained flat by 0.0% to $2.01M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 59.8%, from $1.26M to $2.01M. Over 4 years (FY 2021 to FY 2025), Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan shows an upward trend with a 43.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher values suggest strong employee engagement and participation in equity-based compensation programs.
Detailed definition
This metric represents cash inflows from employees purchasing company stock through formal employee stock purchase plans...
Peer comparison
Standard across most public companies with established employee benefit programs.
financing_proceeds_from_issuance_of_common_stock_under_e_374931Historical Data
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $1.88M | $1.86M | $3.32M | $5.03M | $8.04M |
| YoY Change | — | -0.6% | +78.0% | +51.6% | +59.8% |
Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan at Other Companies
Frequently Asked Questions
- What is Revolution Medicines, Inc.'s proceeds from issuance of common stock under employee stock purchase plan?
- Revolution Medicines, Inc. (RVMD) reported proceeds from issuance of common stock under employee stock purchase plan of $2.01M in Q4 2025.
- How has Revolution Medicines, Inc.'s proceeds from issuance of common stock under employee stock purchase plan changed year-over-year?
- Revolution Medicines, Inc.'s proceeds from issuance of common stock under employee stock purchase plan increased by 59.8% year-over-year, from $1.26M to $2.01M.
- What is the long-term trend for Revolution Medicines, Inc.'s proceeds from issuance of common stock under employee stock purchase plan?
- Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s proceeds from issuance of common stock under employee stock purchase plan has grown at a 43.9% compound annual growth rate (CAGR), from $1.88M to $8.04M.
- What does proceeds from issuance of common stock under employee stock purchase plan mean?
- Cash received from employees buying company stock through company-sponsored purchase programs.